EGFR L718V (+)/T790M (–) as a Mechanism of Resistance in Patients with Metastatic Non–small-cell Lung Cancer with EGFR L858R Mutations
- 8 April 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 22 (6), e817-e819
- https://doi.org/10.1016/j.cllc.2021.03.018
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR MutationsCancer Research, 2020
- Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to AfatinibJournal of Thoracic Oncology, 2019
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancerBritish Journal of Cancer, 2019
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung CancerClinical Cancer Research, 2019
- Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer PatientTargeted Oncology, 2019
- Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based MethodologiesClinical Cancer Research, 2018
- Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinibLung Cancer, 2018
- Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2018
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerThe New England Journal of Medicine, 2017
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015